Novo Holdings

Novo Holdings has co-led the oversubscribed £230 million Series C investment round in OMass Therapeutics, a new portfolio company, together with Bain Capital Life Sciences and Forbion. OMass has built its pipeline of differentiated small-molecule agents based on a breakthrough drug discovery platform interrogating key disease targets that have been well validated but inadequately drugged to date. Each of OMass's candidates has the potential to address substantial unmet patient needs in its respective area of endocrinology or immunology. The round was also joined by existing investors Syncona Limited, Oxford Science Enterprises, GV (Google Ventures), Northpond Ventures, Sanofi Ventures, British Business Bank and University of Oxford, as well as new investors Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. https://lnkd.in/ejEqSFUs

During New York Climate Week, Novo Holdings co-hosted a roundtable and reception with World Economic Forum, C40 Cities, and Urban Partners, bringing together investors, policymakers, innovators, and entrepreneurs to discuss approaches to building future urban competitiveness. One number summed up the scale of the task: global urban climate finance needs have been estimated at up to five trillion dollars per year, according to Cities Climate Finance Leadership Alliance (CCFLA). Our Planetary Health Investments team joined the conversation on how to raise and deploy this capital need.

We are looking for an Associate to join the Quantum Investments team at Novo Holdings in Copenhagen. In this role, you will play a central role across the full investment lifecycle - from sourcing and evaluating opportunities, through transaction execution and due diligence, to active ownership and portfolio value creation. https://lnkd.in/egH8ibXV

Responsible investment is often presented as a choice between impact and performance. For Novo Holdings, there is no trade-off. In this interview from our 2025 Responsible Investment Report, CEO Kasim Kutay and CFO Nigel Govett discuss why responsible investment is core to how we create long-term value, how foundation ownership influences the way Novo Holdings invests, and why supporting certain innovation requires patient capital. They also explain how Novo Holdings seeks to generate attractive financial returns while investing in businesses that benefit people and the planet. Read the full interview: https://lnkd.in/esAGjCXn

Novartis has agreed to acquire Myricx Bio, a Novo Holdings portfolio company developing a novel class of payloads for antibody-drug conjugates (ADCs) in cancer. The transaction is valued at up to USD 1.5 billion, including USD 1.1 billion cash upfront, plus potential milestone payments. Novo Holdings co-led Myricx Bio's USD 114 million Series A in 2024 alongside Abingworth. The financing supported development of Myricx Bio's N-myristoyltransferase inhibitor (NMTi) payload platform. NMT is an enzyme that plays a key role in cancer cell survival. Myricx Bio's differentiated NMTi payload platform is designed to address limitations associated with existing ADC payload classes and has the potential to widely expand the application of ADCs across multiple tumour settings. Learn more about Myricx Bio, and the transaction here: https://lnkd.in/e8HxjF_e #VentureInvestments #InvestorsinLifeSciences

During London Climate Action Week, Novo Holdings’ Planetary Health Investments team brought together investors, founders, and industry leaders to discuss the future of the energy transition. In this video, Senior Partner Cynthia Kueppers shares why affordable, secure, and clean energy are not competing priorities, but must be pursued together. Planetary Health Investments is Novo Holdings' investment platform for backing science-based solutions that benefit the planet while generating attractive returns. Energy transition is one of the team's four core investment themes.